Table 1 Summary of patients evaluated in this study
Histology and clinical background | Number of patients | Sex | Median age (range) | TNM Stage | AJCC stage | Clinical stage | Clinical status | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Male | Female | Ⅰ | Ⅱ | Ⅲ | Ⅳ | NA | T | N | M | Localized | Locally advanced | Metastasis | No evidence of disease | Alive with disease | Dead of disease | Death from other causes | |||||||||
1 | 2 | 3 | 4 | NA | 0 | 1 | 0 | 1 | |||||||||||||||||
Clear cell RCC | 24 | 15 | 9 | 66.5 (24–87) | 15 | 0 | 5 | 4 | 0 | 16 | 0 | 8 | 0 | 0 | 23 | 1 | 20 | 4 | 16 | 4 | 4 | 17 | 2 | 3 | 2 |
Clear cell RCC developed in VHL disease | 8 | 7 | 1 | 39 (22–51) | 8 | 0 | 0 | 0 | 0 | 8 | 0 | 0 | 0 | 0 | 8 | 0 | 8 | 0 | 8 | 0 | 0 | 8 | 0 | 0 | 0 |
Clear cell RCC in hemodialysis patients | 16 | 13 | 3 | 68 (49–76) | 16 | 0 | 0 | 0 | 0 | 16 | 0 | 0 | 0 | 0 | 16 | 0 | 16 | 0 | 16 | 0 | 0 | 16 | 0 | 0 | 0 |
Clear cell RCC with sarcomatoid change | 12 | 7 | 5 | 63.5 (42–73) | 1 | 1 | 4 | 6 | 0 | 3 | 1 | 7 | 1 | 0 | 9 | 3 | 6 | 6 | 2 | 4 | 6 | 4 | 3 | 5 | 0 |
Papillary RCC | 33 | 27 | 6 | 69 (36–84) | 25 | 1 | 5 | 2 | 0 | 26 | 2 | 5 | 0 | 0 | 31 | 2 | 31 | 2 | 26 | 4 | 3 | 28 | 3 | 2 | 0 |
Papillary RCC in hemodialysis patients | 4 | 2 | 2 | 44.5 (32–49) | 4 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 4 | 0 | 4 | 0 | 4 | 0 | 0 | 3 | 0 | 0 | 1 |
Papillary RCC with sarcomatoid change | 1 | 1 | 0 | 75 (75) | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
Chromophobe RCC | 22 | 12 | 10 | 59.5 (35–77) | 20 | 0 | 1 | 0 | 1 | 21 | 0 | 1 | 0 | 0 | 22 | 0 | 22 | 0 | 21 | 1 | 0 | 22 | 0 | 0 | 0 |
Chromophobe RCC developed in BHD syndrome | 10 | 5 | 5 | 50 (49–64) | 10 | 0 | 0 | 0 | 0 | 10 | 0 | 0 | 0 | 0 | 10 | 0 | 10 | 0 | 10 | 0 | 0 | 10 | 0 | 0 | 0 |
Chromophobe RCC in hemodialysis patients | 2 | 1 | 1 | 60.5 (50–71) | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 2 | 0 | 2 | 0 | 2 | 0 | 0 | 2 | 0 | 0 | 0 |
Chromophobe RCC with sarcomatoid change | 2 | 1 | 1 | 72.5 (62–83) | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 2 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 0 |
Oncocytoma | 5 | 3 | 2 | 69 (62–77) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5 | 0 | 0 | 5 | 0 | 0 | 0 |
Hybrid oncocytic chromophobe tumor | 4 | 2 | 2 | 40 (34–64) | 4 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 4 | 0 | 4 | 0 | 4 | 0 | 0 | 4 | 0 | 0 | 0 |
Other oncocytic tumors of the kidney | 5 | 2 | 3 | 69 (61–73) | 5 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 5 | 0 | 5 | 0 | 5 | 0 | 0 | 3 | 0 | 0 | 2 |
Clear cell papillary RCC | 5 | 2 | 3 | 72 (43–81) | 5 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 5 | 0 | 5 | 0 | 5 | 0 | 0 | 5 | 0 | 0 | 0 |
Clear cell papillary RCC in VHL disease | 2 | 1 | 1 | 45 (28–62) | 2 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 0 | 2 | 0 | 0 | 0 |
TFE3-rearranged RCC | 8 | 3 | 5 | 39 (17–70) | 6 | 0 | 1 | 1 | 0 | 7 | 0 | 1 | 0 | 0 | 8 | 0 | 7 | 1 | 6 | 1 | 1 | 7 | 1 | 0 | 0 |
Mucinous tubular spindle cell carcinoma | 5 | 2 | 3 | 60 (45–64) | 3 | 1 | 0 | 1 | 0 | 3 | 1 | 0 | 1 | 0 | 4 | 1 | 4 | 1 | 4 | 0 | 1 | 4 | 1 | 0 | 0 |
Tubulocystic RCC | 4 | 2 | 2 | 65.5 (40–79) | 4 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 4 | 0 | 4 | 0 | 4 | 0 | 0 | 4 | 0 | 0 | 0 |
FH-deficient RCC | 6 | 5 | 1 | 38 (32–52) | 2 | 0 | 2 | 2 | 0 | 3 | 0 | 3 | 0 | 0 | 5 | 1 | 3 | 3 | 2 | 2 | 2 | 3 | 1 | 2 | 0 |
SDH-deficient RCC | 1 | 1 | 0 | 25 (25) | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
Collecting duct carcinoma | 2 | 0 | 2 | 73 (68–78) | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 |
Acquired cystic disease-associated RCC | 14 | 11 | 3 | 59 (41–71) | 12 | 0 | 0 | 0 | 2 | 12 | 0 | 0 | 0 | 2 | 14 | 0 | 14 | 0 | 14 | 0 | 0 | 13 | 0 | 0 | 1 |
Epithelioid angiomyolipoma | 6 | 2 | 4 | 58 (34–81) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4 | 2 | 0 | 5 | 0 | 1 | 0 |
Multilocular cystic renal neoplasm | 2 | 1 | 1 | 41 (35–47) | 2 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 0 | 2 | 0 | 0 | 0 |
Wilms tumor | 1 | 0 | 1 | 6 (6) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
Metanephric adenoma | 2 | 1 | 1 | 38 (17–59) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2 | 0 | 0 | 2 | 0 | 0 | 0 |
Juxtaglomerular cell tumor | 1 | 0 | 1 | 30 (30) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
Invasive urothelial carcinoma | 1 | 0 | 1 | 50 (50) | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 |
Unclassified RCC | 14 | 9 | 5 | 53.5 (19–81) | 4 | 0 | 6 | 4 | 0 | 5 | 0 | 9 | 0 | 0 | 10 | 4 | 10 | 4 | 4 | 5 | 5 | 5 | 6 | 3 | 0 |
Unclassified RCC with sarcomatoid change | 5 | 4 | 1 | 58 (24–70) | 1 | 0 | 0 | 4 | 0 | 1 | 0 | 3 | 1 | 0 | 3 | 2 | 1 | 4 | 1 | 0 | 4 | 0 | 2 | 3 | 0 |
Total | 227 | ||||||||||||||||||||||||
